healthcare, IMS Health, market access, patients, pharma, UK
0 Comment
Available on Demand: Measuring the cost of the right interventions in diabetes.
cancer, commercial, HEOR, IMS Health, market access, marketing, NHS, NICE, Oncology, pharma
0 Comment
Available on demand: A one-hour live debate on Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes.
market access, patient centricity, patients
0 Comment
Several elements are coming together to transform companies’ approaches to meeting health needs.
21/07/2016
healthcare, IMS Health, market access, NHS, pharmacy
0 Comment
New measures proposed by the Government will impact community pharmacies across the UK.
Biogen, biosimilars, Biotech, Humira, market access, Rheumatoid arthritis, rheumatology
0 Comment
Gamble on opicinumab looks unlikely to pay off.
Digital / Social media, market access, nephrology, NICE, pricing, Rare diseases, reimbursement
0 Comment
But NHS refuses £340,000 a year treatment.
advanced therapies, market access, regulation
0 Comment
Only a handful of products have reached the market in eight years.
adherence, apps, clinical trials, communications, digital health, IT / Technology, market access, mobile health, pharma, smartphones, wearables
0 Comment
Balance engagement and compliance with a non-promotional, patient-centric approach and ongoing development for app success.
AAR, Accelerated Access Review, market access, NHS England, UK
0 Comment
What can the AAR do for the UK pharma industry, the health service and patients?
